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sparing.  
Materials and Methods: We retrospectively analyzed 10 adult 
patients undergoing CSI at our institution. All patients were 
treated with TomoTherapy (Accuray, Palo Alto, USA). For 
comparison, all treatment plans were standardized for 
delivery of 36 Gy. The plans were not specifically optimized 
for bone marrow sparing. Additionally, for each patient we 
calculated a 3D conventional plan (3D-CRT) using two 
opposed cranial fields with two attached spinal fields. Based 
on the published data by J.A.Hayman et al. active bone 
marrow compartments were delineated. We compared the 
treatment plans (TomoTherapy vs. 3D-CRT) with respect to 
the mean values for the whole active bone marrow and 
calculated 'weighted bone marrow exposure' (WBME). We 
defined WBME as the sum of all products of mean 
proliferating bone marrow according to anatomical site and 
the mean dose to the anatomical site based on the results of 
J.A. Hayman et al.: WBME =∑(mean marrow according to 
anatomical site * mean dose to anatomical site). 
Results: Mean of mean doses accross all patients for the 
particular bone marrow compartments are shown in the table 
1. Mean values for the whole active bone marrow were higher 
in TomoTherapy plans for each patient with the mean 
difference of ca. 19% (Range 13-37%). Also when taken into 
account the WBME, TomoTherapy treatment plans delivered 
higher dose to active bone marrow in each patient, however 
the mean difference was lower – ca. 13% (Range 2-25%). 
Table 1: Mean of mean doses according to the particular 
bone marrow compartment 
 
 
Conclusions: If not optimized to spare active bone marrow 
CSI, 3D-CRT is superior to TomoTherapy with respect to 
active bone marrow sparing. Except for the sternum, 3D-CRT 
results in almost equivalent or better dose sparing of all bone 
marrow compartments. To evaluate the bone marrow sparing 
the use of WBME seems prudent as the quantitative active 
bone marrow distribution doesn’t follow the absolute bone 
marrow distribution. Whether active bone marrow sparing 
optimized TomoTherapy plans yield superior results is a 
matter of ongoing research. 
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Purpose/Objective: Proper staging of intracranial disease 
with an accurate assessment of the exact number of brain 
lesions is of utmost importance in the decision-making 
process for the appropriate treatment of patients with brain 
metastases. The diagnostic efficacy in the detection of 
additional brain metastases of a three-dimensional, T1-
Weighted Gradient-Echo Imaging with a double contrast was 
evaluated 
Materials and Methods: Before undergoing radiosurgical 
treatment, patients underwent a brain magnetic resonance 
imaging (MRI) scan to be used during the treatment planning 
in order to contour the targets and to locate the brain lesions 
as they relate to the stereotactic frame.  
All the patients underwent a post-contrast study with T1-
weighted, 3D Magnetization-Prepared Rapid Acquisition 
Gradient Echo (MP RAGE) sequence. We used a double dose 
of gadobenate dimeglumine and slice thickness of 1 mm.  
Results: Starting from October 2012 to August 2014, we 
treated with Gamma Knife radiosurgery (GKRS) 113 patients 
with brain metastases. On the diagnostic MRI, all the patients 
had a number of lesions ≤4. Median time interval between 
diagnostic MRI scan and the day of GKRS was 13 days (range 
5-22)  
A total of 87 additional lesions were detected on MR imaging 
performed in the same day of the GKRS in forty patients out 
of 113 (35.4%). A median number of 2 additional lesions were 
detected (range 1-11). Among these 40 patients only 18 
patients had a number of lesions ≤4 on the day of treatment. 
Patients with a total number of lesions ≤10 were treated with 
GKRS. Two patients with a total number of lesions > 10 were 
treated with whole brain radiotherapy (WBRT).  
Conclusions: A double-contrast study with T1-weighted, 
volumetric MPRAGE sequence, using acquisition of contiguous 
1-mm slices may offer a definitely better staging for patients 
with brain metastases. In our opinion, a diagnostic high 
resolution MRI should be recommended in all the patients 
with newly diagnosed brain metastases because the detection 
of the real number of lesions is crucial for an adequate 
treatment and it also may lead to choose different 
therapeutic strategies other than radiosurgery.  
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Purpose/Objective: CNAO (Centro Nazionale di Adroterapia 
Oncologica) started clinical activity with proton beam in 
